Facebook
Twitter
LinkedIn
ForwardNCCN 2020 Virtual Nursing Forum: Advancing Oncology Nursing in Hematologic Malignancies™
The management of cancer is constantly evolving through the introduction of new advances related to cancer treatment and supportive care. This program will provide hematology/oncology nurses with comprehensive and clinically relevant information to optimize patient education and care. Information is focused on current and critical issues to provide hematology/oncology nurses with practical information that can be implemented in the practice setting.
Target Audience
This educational program is designed to meet the educational needs of hematology/oncology nurses and nurse practitioners who manage patients with hematologic malignancies.
Learning Objectives
The goal of this activity is to ensure that hematology/oncology nurses, as members of the interprofessional oncology care team, have the knowledge and skills necessary to apply the standards of care to their practice and health care setting for patients with hematologic malignancies. Following this program, participants should be able to:
- Evaluate advances in the management of patients with hematologic malignancies and key updates in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and apply appropriate treatment and supportive care strategies to optimize patient education and care.
- Review issues related to optimizing outpatient care in hematopoietic cell transplant patients, strategies to reduce Clostridioides difficile (C. diff) infection in hematologic malignancies, management of cardiac complications, and advances an innovations in the treatment of multiple myeloma.
Session Learning Objectives
Optimizing Outpatient Care in Hematopoietic Cell Transplant Patients
- Explain the rationale for optimizing outpatient care in a hematopoietic cell transplant (HCT) program.
- Identify the resources needed to optimize an outpatient HCT program.
- Discuss nursing implications for patients receiving transplant care in the outpatient setting.
Strategies to Reduce Clostridioides Difficile Infection in Hematologic Malignancies
- Recognize the risk of Clostridioides Difficile (C. diff) colonization and infection in patients with hematologic malignancies, including hematopoietic cell transplant (HCT) recipients.
- Discuss strategies for screening for C. diff infection in patients with hematologic malignancies, including HCT recipients.
- Describe treatment options for patients with hematologic malignancies who develop C. diff infection, including HCT recipients.
Management of Cardiac Complications in Hematologic Malignancies
- Outline the key features of at least three cardiac toxicities pertinent to practice with patients having hematologic malignancies.
- Describe methods of minimizing the risk for cardiotoxicity with patients having hematologic malignancies.
- In a given case scenerio of an individual at risk or experiencing potential cardiac toxicities, define the priority interventions.
Advances and Innovations in the Treatment of Multiple Myeloma
- Outline currently recommended combination therapies for relapsed/refractory multiple myeloma (MM).
- Discuss supportive care measures needed for patients with MM as a result of the disease and/or treatment, and outline strategies to manage them.
- Review emerging treatment options and employ effective communication strategies that will help convey the benefits and risks of clinical trial participation to patients.
NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics).
Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.
Definitions
NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.
NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.
Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.
Faculty Disclosures
The faculty listed below discloses no relevant financial relationships:
Marci Andrejko, DNP, APRN, FNP-C
Misty Lamprecht, MS, APRN-CNS, AOCN, BMTCN
Brenda Shelton, DNP, APRN-CNS, CCRN, AOCN
The faculty listed below discloses the following relevant financial relationships:
Patricia Mangan, RN, MSN, APRN-BC
Amgen Inc.: Product/Speakers Bureau
Bristol-Myers Squibb Company: Product/Speakers Bureau
Celgene Corporation: Product/Speakers Bureau
GlaxoSmithKline: Product/Speakers Bureau
Janssen Pharmaceutica Products, LP: Product/Speakers Bureau
Karyopharm Therapeutics: Product/Speakers Bureau
sanofi-aventis U.S. : Product/Speakers Bureau
NCCN Staff Disclosures
The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Michael Abrams; Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa Perfidio, MS; Shannon Ryan, CMP; Kathy Ann Smith, CHCP; Sarah Weinstein
The NCCN Leadership listed below discloses no relevant financial relationships:
Robert W. Carlson, MD; Gary J. Weyhmuller, MBA, SPHR
The NCCN Leadership listed below discloses the following relevant financial relationships:
Wui-Jin Koh, MD: IBM Watson Health for Oncology and Genomics; Scientific Advisor
The NCCN Clinical staff listed below discloses no relevant financial relationships:
Jennifer L. Burns, BS; Giby V. George, MD; Jennifer Keller; Rashmi Kumar, PhD; Angela Motter, PhD; Lenora Pluchino, PhD; Dorothy A. Shead, MS
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurse Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NCCN designates this educational activity for a maximum of 3 contact hours.
Available Credit
- 3.00 ANCC contact hours
- 3.00 Participation
Price
Click the Take Course button to start the credit claiming process.
Required Hardware/software
To complete this activity, users will need:
- A device with an Internet connection
- Adobe Reader or other PDF reader software for certificate viewing/printing